FOSUN INTL(HK:00656) Zhong Guo Jin Rong Xin Xi Wang·2025-08-29 08:29Core Viewpoint - Fosun International's Chairman Guo Guangchang emphasized the company's commitment to increasing investments in the biopharmaceutical sector, aiming to deepen its focus on advantageous industries and capture global market leadership [1]. Group 1: Business Performance - In the first half of the year, Fosun achieved significant breakthroughs across multiple business segments, particularly in the biopharmaceutical sector [1]. - The company is poised to leverage growth opportunities through technological innovation to achieve breakthrough advancements [1]. Group 2: Innovation Drug Development - Fosun has a pipeline of innovative drug candidates with a potential global market size ranging from $5 billion to $10 billion [1]. - In addition to its subsidiary, Fuhong Hanlin, Fosun is advancing its CAR-T technology platform and other innovative drug developments, which present substantial growth potential [1]. Group 3: Strategic Approach - Guo highlighted the importance of both licensing in and licensing out for innovative drugs, indicating a strategic approach to not rush into licensing agreements, even if they may yield high prices [1]. - The company aims to build its global capabilities in research and development, clinical trials, and sales within the biopharmaceutical field, which is seen as a fundamental pathway for Fosun to evolve into a global pharmaceutical giant [1].